Tadalafil 5 mg daily (Cialis), also indicated for the treatment of signs and symptoms of benign prostatic hyperplasia

Following  시알리스 구매  by the European Commission at the end of 2012, the company Lilly has announced that the Spanish health authorities have authorized the new indication for tadalafil 5 mg daily (Cialis) for the treatment of the signs and symptoms of benign prostatic hyperplasia. In this way, Cialis becomes the first and only effective drug to simultaneously treat erectile dysfunction and the signs and symptoms of benign prostatic hyperplasia, coexisting pathologies in a large number of middle-aged and elderly men.

This new indication for tadalafil 5 mg daily is based on a clinical study program made up of four trials that included 1,500 men with urinary symptoms due to BPH. In one of these studies, men with both pathologies were also included: BPH and erectile dysfunction. These clinical trials have already allowed the authorization of Cialis 5 mg for the treatment of the signs and symptoms of BPH in the United States, Canada, Mexico, Brazil, South Korea, Russia, Panama, Argentina, Honduras, Ecuador, Costa Rica, Colombia, Israel and, now, Spain.

For the treatment of erectile dysfunction, Cialis has been approved in all countries belonging to the European Union since 2007.

"Given the high number of men who, over the age of fifty, suffer from both diseases, we believe that -thanks to this new indication- Spanish men have a very valuable therapeutic option as the same drug treats both pathologies", assures José Antonio Sacristán, medical director of Lilly Spain, who states that Lilly considers it a priority to continue researching in the area of ​​Urology "because we are committed to providing new treatment options to the millions of men who suffer from erectile dysfunction, signs and symptoms due to BPH and other urologic conditions.